Terumo India unveils advanced simulation-based training

IMT News Desk
IMT News Desk
· 2 min read

The new training room at TISL, which can accommodate up to 32 people, is equipped with audio and video conferencing capabilities to facilitate remote learning and collaboration

Terumo India has taken a significant step forward in its group mission of ‘contributing to society through healthcare’ with the advancement of its Terumo India Skill Lab (TISL). The state-of-the-art facility, designed to enhance the clinical skills of healthcare professionals (HCPs), has been upgraded recently to offer specialised simulation-based training.

The advanced TISL includes cutting-edge equipment to enhance simulation training for complex cardiovascular and interventional procedures. Among the new additions are the Mentice computer-based simulator and physical training models, designed to simulate various interventional procedures. These tools enable healthcare professionals to better prepare for real-world scenarios and achieve optimal patient outcomes.

Notably, a Beating Heart Model has been introduced to simulate the movement of the heart as it beats. At the same time, a Liver Flow Model and Iliac Model have been added to train interventional radiologists for minimally invasive procedures.

Dr Anudeep Sandhu, Director of Medical Affairs and Clinical Affairs, said, “By advancing Terumo India Skill Lab, we are directly addressing the critical need for enhanced HCP training in India, where complex procedures like percutaneous coronary interventions (PCI) are becoming increasingly vital. Our state-of-the-art facility equips healthcare professionals with the advanced skills needed to manage complications effectively. Our commitment to clinical excellence and pioneering academic initiatives through TISL will not only elevate healthcare practices but also contribute to improving patient outcomes across the country.”

The new training room at TISL, which can accommodate up to 32 people, is equipped with audio and video conferencing capabilities to facilitate remote learning and collaboration. By partnering with academic institutes, teaching hospitals, and scientific societies, Terumo India is enhancing physician training, minimising errors, and improving patient outcomes.

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk